Parse Biosciences GigaLab to Support Mount Sinai Researchers in Generating One of the Largest Alzheimer's and Parkinson's Single Cell Datasets
Researchers aim to understand mechanisms of alternative splicing in neurodegenerative disease
Article content
SEATTLE — Parse Biosciences today announced their commitment to support researchers from the Icahn School of Medicine at Mount Sinai in generating one of the largest single cell datasets focused on understanding alternative splicing events in the cells of Alzheimer's and Parkinson's patients. The study's initial phase will analyze transcriptomic profiles from more than 10 million cells derived from more than 1,000 peripheral blood mononuclear cell (PBMC) samples of patients with neurodegenerative conditions. The data amassed from these analyses will lay the foundation for discoveries that could transform how these diseases are understood, detected, and treated.
Article content
'Historical research in neurodegenerative disease has focused on the genomic underpinnings for disease diagnoses, but few have looked at the post transcriptional events that may be further driving pathology and progression of disease,' said Towfique Raj, PhD, principal investigator in the laboratory for functional genomics and core faculty member of the Ronald M. Loeb Center for Alzheimer's Disease at Mount Sinai, who will lead this study. 'We're excited to be able to look at alternative splicing events in single cells at scale to determine alternative contributors to disease onset, progression and severity. Studies of this scale are critical to the development of foundational models to help us better understand neurodegenerative disease.'
Article content
Dr. Raj's research team at Mount Sinai is dedicated to understanding the molecular mechanisms of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and ALS (amyotrophic lateral sclerosis).
For this study, the Mount Sinai team is working to conduct high-throughput profiling on banked PBMCs donated by patients with confirmed Alzheimer's disease or Parkinson's disease diagnoses. The researchers expect to profile more than 1,000 samples in order to capture single cell whole transcriptome repertoire data on them. The samples that have been prepared at Mount Sinai will then be sent to Parse GigaLab, a state-of-the-art facility purpose-built for the generation of massive-scale single cell RNA sequencing datasets. Leveraging Parse's Evercode chemistry, the GigaLab can rapidly produce large single cell datasets with exceptional quality.
Article content
'We are incredibly excited to bring the power of GigaLab to elevate the impactful work the Raj Lab has been driving,' says Dr. Charlie Roco, Chief Technology Officer at Parse Biosciences. 'The speed and scale achieved with the GigaLab truly helps to accelerate research and get us to insights faster than we ever have before.'
Article content
About Parse Biosciences
Article content
Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system.
Article content
With technology developed at the University of Washington by co-founders Alex Rosenberg and Charles Roco, Parse has raised over $100 million in capital and is used by over 2,500 customers across the world. Its growing portfolio of products includes Evercode™ Whole Transcriptome, Evercode™ TCR, Evercode™ BCR, Gene Select, and a solution for data analysis, Trailmaker™.
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
2 hours ago
- National Post
Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial
Article content SAN DIEGO — Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms. Article content Through this collaboration, LabPMM (Invivoscribe's global reference laboratories) have customized their multiparametric flow cytometry (MFC) services and implemented their sensitive MFC AML MRD assay to support CERo's clinical trial of its lead compound, CER-1236. The trial targets Acute Myeloid Leukemia (AML) in patients who are relapsed/refractory, in remission with MRD, or newly diagnosed with TP53-mutated MDS/AML. Article content AML is an aggressive blood cancer characterized by the rapid accumulation of abnormal myeloid cells in the bone marrow and blood, disrupting normal hematopoiesis. 1 Treating AML is especially complex due to its genetic heterogeneity and the high risk of relapse. CAR-T (chimeric antigen receptor T-cells) and Chimeric Engulfment Receptor T-cells ('CER-T') therapies, which involve engineering a patient's own T-cells to recognize and attack cancer cells, have shown promise in other hematologic malignancies and are now being explored for AML. However, because these therapies are manufactured from patient-derived cells, it's critical to confirm that leukemic blasts are not inadvertently included in the final therapeutic product – underscoring the need for sensitive, validated assays like those offered by Invivoscribe and its global accredited regional laboratories, LabPMM. Article content LabPMM's CAP/CLIA-Validated AML MRD MFC assay, which was designed to quantify residual leukemic cells in patients undergoing treatment, was customized to meet two critical needs in CERo's drug development program: (1) assessing the purity of the manufactured T-cell product by detecting residual AML blasts prior to infusion, and (2) evaluating therapeutic response to CER-1236 during the trial. Article content Kristen Pierce, Ph.D., CERo Chief Development Officer, commented, 'Invivoscribe has played an integral role in the execution of this clinical trial. Its technology and expertise have facilitated our advancement into the clinic by helping to ensure the purity of our investigational product, and now we are reaping the benefits of our collaboration as the trial is underway and we seek to assess therapeutic response.' Article content This collaborative effort was instrumental in advancing CER-1236, which recently received FDA Orphan Drug Designation for the treatment of AML 2. The designation highlights the growing urgency of integrated diagnostic support in the advancement of personalized immunotherapies and reflects Invivoscribe's commitment to driving innovation and standardization across the oncology treatment landscape – now helping bring immunotherapies to patients faster. Article content For more information about LabPMM's flow cytometry and molecular testing services, please visit or contact us at inquiry@ and follow us on LinkedIn. Article content About Invivoscribe Inc. Article content Invivoscribe ® is a global, vertically integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics ®. For thirty years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with pharmaceutical companies interested in clinical trial testing via our global lab network located in the U.S., Germany, Japan and China, and in developing and commercializing companion diagnostics, with our rigorous expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM ®), Invivoscribe is an ideal partner from diagnostic development, through clinical trials, regulatory submissions, and commercialization. Article content About CERo Therapeutics Holdings, Inc. Article content CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ('CER-T'). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ('CAR-T') cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo has commenced clinical trials for its lead product candidate CER-1236 for hematological malignancies. Article content Article content Article content Article content Article content Article content
Globe and Mail
5 hours ago
- Globe and Mail
Gastrointestinal Stromal Tumor Pipeline strong with 25+ Companies driving therapeutic innovation: DelveInsight
DelveInsight's, 'Gastrointestinal Stromal Tumors Pipeline Insight 2025' report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Gastrointestinal Stromal Tumors pipeline landscape. It covers the Gastrointestinal Stromal Tumors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Gastrointestinal Stromal Tumors pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Gastrointestinal Stromal Tumors Pipeline. Dive into DelveInsight's comprehensive report today! @ Gastrointestinal Stromal Tumors Pipeline Outlook Key Takeaways from the Gastrointestinal Stromal Tumors Pipeline Report In June 2025, Merck Sharp & Dohme LLC announced a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced wt (wild-type) gastrointestinal stromal tumor (wt GIST), or advanced solid tumors with hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterations. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR). In June 2025, Novartis Pharmaceuticals conducted a study planned a 6-month recruitment phase to enroll 40 subjects, followed by a 6-month treatment phase with monthly visits. Patients benefiting from the treatment could continue during a follow-up phase. In June 2025, Deciphera Pharmaceuticals LLC organized a Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module being defined according to therapy: DCC-3009 alone or DCC-3009 in combination with other anticancer therapies. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). Participants will be treated in 28-day treatment cycles with an estimated duration of up to 2 years. DelveInsight's Gastrointestinal Stromal Tumors Pipeline analysis depicts a robust space with 25+ active players working to develop 28+ pipeline treatment therapies. The leading Gastrointestinal Stromal Tumors Companies such as Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others. Promising Gastrointestinal Stromal Tumors Therapies such as Belzutifan, Sunitinib, CGT9486, DCC-3116, Ripretinib, UCB4594, and others. Stay ahead with the most recent pipeline outlook for Gastrointestinal Stromal Tumors. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Gastrointestinal Stromal Tumors Approved Drugs Gastrointestinal Stromal Tumors (GIST) Emerging Drugs Famitinib: Jiangsu Hengrui Medicine Famitinib, an orally active, small molecule, is a tyrosine kinase inhibitor against multiple targets, including vascular endothelial growth factor receptor 2/3, platelet-derived growth factor receptor, and stem cell factor receptor (c-kit). Jiangsu Hengrui Medicine Co is developing famitinib against a wide variety of advanced-stage solid cancers. The drug is currently in phase 3 of clinical development for the treatment of Gastrointestinal Stromal Tumors (GIST). Nilotinib: Novartis Tasigna (nilotinib hydrochloride monohydrate) is an orally available signal transduction inhibitor of the Bcr-Abl kinase, c-kit and Platelet Derived Growth Factor (PDGF), all of which play a role in cell proliferation, cell migration, and angiogenesis. Tasigna is specifically indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant or intolerant to prior therapy that included imatinib. The drug is currently being investigated in Phase II clinical trial to evaluate its potential for the treatment of gastrointestinal stromal tumors. THE-630: Theseus Pharmaceuticals THE-630 is a pan-variant inhibitor of the receptor tyrosine kinase KIT. It is designed for patients with advanced GIST whose cancer has developed resistance to earlier lines of therapy by accruing mutations that render those therapies ineffective. In GIST, these mutations occur most often in the KIT protein, where a patient can have multiple KIT mutations simultaneously, leading to complex disease heterogeneity. In preclinical studies, THE-630 demonstrated potent in vitro and in vivo activity against all major classes of KIT activating and resistance mutations in GIST. Moreover, THE-630 achieved predicted pan-variant KIT inhibitory blood concentrations at tolerable doses and was associated with significant anti-tumor activity. Theseus Pharmaceuticals is currently conducting Phase I/II study to evaluate lead candidate, THE-630, in patients with advanced gastrointestinal stromal tumors (GIST). DS 6157: Daiichi Sankyo Company DS-6157 is a potential first-in-class GPR20 targeting ADC and the fifth DXd ADC in the oncology pipeline of Daiichi Sankyo to enter clinical development. ADCs are targeted cancer medicines that deliver cytotoxic chemotherapy ('payload') to cancer cells via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells. Designed utilizing Daiichi Sankyo's proprietary DXd ADC technology, DS-6157 is comprised of a humanized anti-GPR20 monoclonal antibody, which is attached to a novel topoisomerase I inhibitor payload by a tetrapeptide-based linker. The drug is currently in Phase I stage of clinical trial evaluation to treat Gastrointestinal Stromal Tumors. The Gastrointestinal Stromal Tumors pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Gastrointestinal Stromal Tumors with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastrointestinal Stromal Tumors Treatment. Gastrointestinal Stromal Tumors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Gastrointestinal Stromal Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gastrointestinal Stromal Tumors market. Explore groundbreaking therapies and clinical trials in the Gastrointestinal Stromal Tumors Pipeline. Access DelveInsight's detailed report now! @ Gastrointestinal Stromal Tumors Treatment Drugs Gastrointestinal Stromal Tumors Companies Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others. Gastrointestinal Stromal Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration Oral Parenteral Intravenous Subcutaneous Topical Gastrointestinal Stromal Tumors Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Unveil the future of Gastrointestinal Stromal Tumors Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Gastrointestinal Stromal Tumors Market Drivers and Barriers Scope of the Gastrointestinal Stromal Tumors Pipeline Report Coverage- Global Gastrointestinal Stromal Tumors Companies- Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others. Gastrointestinal Stromal Tumors Therapies- Belzutifan, Sunitinib, CGT9486, DCC-3116, Ripretinib, UCB4594, and others. Gastrointestinal Stromal Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Gastrointestinal Stromal Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Gastrointestinal Stromal Tumors Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Gastrointestinal Stromal Tumors Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary Gastrointestinal Stromal Tumors: Overview Pipeline Therapeutics Therapeutic Assessment Gastrointestinal Stromal Tumors – DelveInsight's Analytical Perspective Late Stage Products (Phase III) Famitinib: Jiangsu Hengrui Medicine Drug profiles in the detailed report….. Mid Stage Products (Phase II) Nilotinib: Novartis Drug profiles in the detailed report….. Early Stage Products (Phase I) DS 6157: Daiichi Sankyo Company Drug profiles in the detailed report….. Inactive Products Gastrointestinal Stromal Tumors Key Companies Gastrointestinal Stromal Tumors Key Products Gastrointestinal Stromal Tumors- Unmet Needs Gastrointestinal Stromal Tumors- Market Drivers and Barriers Gastrointestinal Stromal Tumors- Future Perspectives and Conclusion Gastrointestinal Stromal Tumors Analyst Views Gastrointestinal Stromal Tumors Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
CTV News
6 hours ago
- CTV News
Rare ‘corpse plant' blooms at Austin Peay University drawing visitors
Austin Peay University is home to two extremely rare corpse plants, with fewer than 1,000 existing worldwide. (WTVF via CNN Newsource) CLARKSVILLE, Tennessee (WTVF) - A botanical rarity is drawing attention at Austin Peay University, where one of the world's most unusual plants is putting on a spectacular but brief show. Unlike its name, the corpse plant is very alive. But it earned its morbid nickname honestly. 'It's all going to look at smell like rotten flesh,' said Dr. Karen Meisch, Dean of the STEM College at Austin Peay University. Miesch explained that fewer than a thousand of these plants exist in the world today. 'This is the titan arum normally found or natively found in Indonesia on the island of Sumatra,' she said. The university houses two corpse plants. These plants take about seven to ten years to bloom, and when they do, the resulting flower only lasts a day or so. 'Athena's outer leaves dropped Sunday morning and they will typically bloom within 2 to 5 days,' Meisch said. Athena's bloom takes just two weeks to grow from a small sprout into a towering flower, and it won't come back for another two to five years. 'Eventually it will go back 100 percent into the soil and it will be there for about 3-4 months,' Meisch said. In between flowerings, the plant grows for nine-month periods, falls off, and continues the cycle. 'Even though it looks like a tree it is a single leaf,' Meisch said. The flower attracts beetles with its pungent smell when it blooms to pollinate. 'The beetles have to find another flower that's in bloom in that 24-hour period,' Meisch said. This rare bloom reminds us to treasure nature's fleeting wonders. By Kim Rafferty.
